Browsing byAuthorEldehna, WM
Showing results 1 to 6 of 6
Issue Date | Title | Author(s) |
2023-04-04 | 1-Benzyl-5-bromo-3-hydrazonoindolin-2-ones as Novel Anticancer Agents: Synthesis, Biological Evaluation and Molecular Modeling Insights. | Al-Warhi, T; Almahli, H; Maklad, RM; Elsayed, ZM; El Hassab, MA; Alotaibi, OJ; Aljaeed, N; Ayyad, RR; Ghabour, HA; Eldehna, WM; El-Ashrey, MK |
2024-12 | Design, synthesis, and in silico insights of novel N'-(2-oxoindolin-3-ylidene)piperidine-4-carbohydrazide derivatives as VEGFR-2 inhibitors. | Eldehna, WM; Habib, YA; Mahmoud, AE; Barghash, MF; Elsayed, ZM; Elsawi, AE; Maklad, RM; Rashed, M; Khalil, A; Hammad, SF; Ali, MM; El Kerdawy, AM |
2021-12 | Development of 3-methyl/3-(morpholinomethyl)benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells. | Al-Sanea, MM; Al-Ansary, GH; Elsayed, ZM; Maklad, RM; Elkaeed, EB; Abdelgawad, MA; Bukhari, SNA; Abdel-Aziz, MM; Suliman, H; Eldehna, WM |
2022-10-27 | Development of novel isatin thiazolyl-pyrazoline hybrids as promising antimicrobials in MDR pathogens. | Al-Warhi, T; Elimam, DM; Elsayed, ZM; Abdel-Aziz, MM; Maklad, RM; Al-Karmalawy, AA; Afarinkia, K; Abourehab, MAS; Abdel-Aziz, HA; Eldehna, WM |
2022-12 | Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and in silico insights. | Eldehna, WM; Maklad, RM; Almahli, H; Al-Warhi, T; Elkaeed, EB; Abourehab, MAS; Abdel-Aziz, HA; El Kerdawy, AM |
2023-09-05 | Tetrahydrobenzo[h]quinoline derivatives as a novel chemotype for dual antileishmanial-antimalarial activity graced with antitubercular activity: Design, synthesis and biological evaluation. | Ibrahim, TM; Abada, G; Dammann, M; Maklad, RM; Eldehna, WM; Salem, R; Abdelaziz, MM; El-Domany, RA; Bekhit, AA; Beockler, FM |